multiplesclerosisnewstoday.com

multiplesclerosisnewstoday.com
Share

A year after U.S. regulators approved Genentech’s Ocrevus (ocrelizumab) as the first treatment for both the relapsing and progressive forms of multiple sclerosis, a prominent neurologist involved in the Phase 3 clinical trials that led to its authorization says it has been a godsend for certain subsets of patients. But it’s simply too early to tell...

AbobotulinumtoxinA, marketed as Dysport Therapeutic by Ipsen Biopharmaceuticals Canada, was approved by Health Canada for the treatment of lower limb focal spasticity in adults. Focal spasticity is a medical disorder characterized by an abnormal increase in muscular stiffness in one or more muscles, and usually is the result of a brain or spinal...

Removing obstructions in large neck veins reduced multiple sclerosis patients’ headaches for several years, British and Italian researchers have demonstrated. The magnitude and duration of the effect differed among patients with different types of MS, however. Researchers also found that the treatment reduced fatigue, particularly in...

multiplesclerosisnewstoday.com

 •  December 4, 2017

Oral steroids may be cheaper, more convenient and less invasive alternatives than intravenous steroids in treating relapses in multiple sclerosis (MS) patients, suggests an analysis of five randomized trials. Glucocorticoids are recommended as the first line of treatment for MS relapses. Yet recent studies have shown no significant difference...

multiplesclerosisnewstoday.com

 •  October 25, 2017

Opicinumab, an investigative treatment aiming to promote remyelination in relapsing multiple sclerosis (MS) patients, will be tested in a new clinical trial — having failed at an earlier effort, but having shown promise enough in particular patients to be worth a closer look. In fact, the new AFFINITY study “is only possible because we learned a...

multiplesclerosisnewstoday.com

 •  October 3, 2017

Fast Forward, a non-profit subsidiary of the National Multiple Sclerosis Society, will give financial support to TG Therapeutics to advance TGR-1202 (umbralisib) into preclinical testing as a potential oral therapy for progressive forms of multiple sclerosis. The support, whose value was not specified, is part of a Sponsored Research Agreement...

multiplesclerosisnewstoday.com

 •  July 25, 2016

Click here to receive MS news via e-mail Sanofi Genzyme announced that the Government of Ontario has added Lemtrada (alemtuzumab) to the province’s Exceptional Access Program (EAP), opening coverage to the treatment for eligible patients with relapsing-remitting multiple sclerosis (RRMS). The program facilitates patient access to drugs not funded...

multiplesclerosisnewstoday.com

 •  October 10, 2015

The new, experimental therapy has made headlines this week after the company ... In terms of safety, Dr. Hauser reported that the most adverse events were infusion-related reactions (especially in the first infusions). In the combined cohort of patients ...